1. Products
  2. Neurology
  3. Kesimpta®
  4. Kesimpta® - Clinical Papers

Kesimpta® - Clinical Papers

November 4, 2021
P1

Ofatumumab versus Teriflunomide in Multiple Sclerosis

 

P2

Ofatumumab Versus Teriflunomide in Multiple Sclerosis - Supplementary Appendix

 

P3

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

 

P3

Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis

 

P3

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

 

Type of content: 
Clinical Papers
Print
×

Medical Information Request

×

Ask Speakers